Alterity Therapeutics Limited, a biotechnology company, has reported positive interim data from its ATH434-202 Phase 2 clinical trial for treating Multiple System Atrophy (MSA). The trial, which is still ongoing, has shown encouraging results with 43% of participants demonstrating improvement in daily living activities and 29% showing stable or improved neurological symptoms after six months of treatment with ATH434. The drug was also well-tolerated with no serious adverse events related to the study drug reported. Additionally, clinical responders exhibited biomarker evidence of stable disease, including reduced accumulation of iron in the brain and stable levels of Neurofilament Light Chain, a marker of axonal injury. The trial's primary objective is to evaluate the impact of 12 months of treatment with ATH434 on brain volume in advanced MSA patients. Final data from the trial are expected in the first half of 2025. ATH434 has previously been granted Orphan drug designation for the treatment of MSA by the U.S. FDA and the European Commission.

Alterity Therapeutics Limited, a biotechnology company, has reported positive interim data from its ATH434-202 Phase 2 clinical trial for treating Multiple System Atrophy (MSA). The trial, which is still ongoing, has shown encouraging results with 43% of participants demonstrating improvement in daily living activities and 29% showing stable or improved neurological symptoms after six months of treatment with ATH434. The drug was also well-tolerated with no serious adverse events related to the study drug reported. Additionally, clinical responders exhibited biomarker evidence of stable disease, including reduced accumulation of iron in the brain and stable levels of Neurofilament Light Chain, a marker of axonal injury. The trial's primary objective is to evaluate the impact of 12 months of treatment with ATH434 on brain volume in advanced MSA patients. Final data from the trial are expected in the first half of 2025. ATH434 has previously been granted Orphan drug designation for the treatment of MSA by the U.S. FDA and the European Commission.